UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2023

Commission File Number: 001-40086

Portage Biotech Inc.

(Translation of registrant's name into English)

<u>N/A</u>

(Translation of registrant's name into English)

British Virgin Islands

(Jurisdiction of incorporation or organization)

<u>Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110</u> (Address of principal executive offices)

rudiess of principal executive off

c/o Portage Development Services Inc., Ian Walters, 203.221.7378

61 Wilton Road, Westport, Connecticut 06880

(Name, telephone, e-mail and/or facsimile number and Address of Company Contact Person)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: 🖂 Form 20-F 🛛 Form 40-F

Exhibits

The following Exhibit is filed with this report:

Exhibit	Description
<u>99.1</u>	Corporate Presentation

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 13, 2023

Portage Biotech, Inc.

By:
Name
Title:

/s/ Allan Shaw Allan Shaw Chief Financial Officer



Corporate Presentation

Nasdaq: PRTG November 2023



Legal Disclaimer



Forward-Looking Information

This presentation contains "forward-looking statements" that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the "Securities Act," and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "strategy," "target," "will," "would" and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the Company's ability to obtain financing in the future to cover its operational costs and progress its plans for clinical development, its estimates regarding its capital requirements, and its ability to continue as a going concern; the Company's plans and ability to develop and commercialize product candidates and the timing of these development programs; the Company's clinical development of its product candidates, including the results of current and future clinical trials; the benefits and risks of the Company's product candidates as compared to others; the Company's maintenance and establishment of intellectual property rights in its product candidates; the Company's estimates of future revenues and profitability; the Company's estimates of the size of the potential markets for its product candidates; its selection and licensing of product candidates; and other factors set forth in "Item 3 - Key Information-Risk Factors" in the Company's Annual Report on Form 20-F for the year ended March 31, 2023, and those discussed in the Company's other reports filed with the Securities and Exchange Commission from time to time. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.




Immuno-Oncology Company with Four First/Best in Class Compounds in the Clinic Multiple Data Catalysts in 2023 and 2024 Experienced Leadership Team from Bristol Myers Squibb Cost-Efficient Business Model Proven Leadership with Oncology and Financing Expertise





Our Formula for Success





Nine Phase 1b/2 Data Catalysts Anticipated to Drive Value



	ASSET	INDICATION	STAGE	# of PTS	Interim Data	Final Data
	PORT-2	Melanoma + NSCLC	Phase 1	18	ASCO 2023	Q1 2024
IST	PORT-3	Solid Tumors	Phase 1^	13		
0	PORT-2	Refractory Melanoma	Phase 2*	10	SITC 2024	ASCO 2025
0	PORT-2+ Keytruda [®]	Front line PD-L1 + NSCLC	Phase 2*	30	SITC 2024	SITC 2025
3	PORT-2+ Keytruda [®]	PD-L1 - NSCLC 2nd/3rd line	Phase 2*	10	SITC 2024	SITC 2025
4	PORT-2+ Keytruda [⊗]	PD-L1 + NSCLC 2 nd line	Phase 2*	15	ASCO 2025	SITC 2025
	ASSET	INDICATION	STAGE	# of PTS	Interim Data	Final Data
	PORT-6 (A2A)	A2A exp Solid Tumors	Phase 1a	21-27	ASCO 2024	SITC 2024
6	PORT-7 (A2B)	A2B exp Solid Tumors	Phase 1a*	18	SITC 2024	ASCO 2025
6	PORT-6 (A2A)	A2B exp Solid Tumors	Phase 1b*	20	SITC 2024	SITC 2025
	PORT-7 (A2B)	A2A exp Solid Tumors	Phase 1b*	20	SITC 2025	ASCO 2026
6 7	PORT-7 (A2B) PORT-6 (A2A) + CPI	A2A exp Solid Tumors A2A exp Solid Tumors	Phase 1b*	20 20	SITC 2025 SITC 2024	ASCO 2026 SITC 2025

ortage

iNKT Engagers PORT-2, PORT-3


Activating the innate, adaptive immune system and correcting the tumor microenvironment









Portage's iNKT Engager (PORT-2): Rationally Designed Liposomal Formulation of IMM60 iNKT in charged liposome to protect lipid chain, aggregate in tumor, and promote Type 1 cytokine release





Multiple Cell Types Needed for Anti-Cancer Response



PORT-2 compound impacts all these pathways, including changing the tumor directly

10 Acquisition activity by large pharma players


Technology Acquired



portage

PORT-2 Demonstrates Robust Pre-Clinical Single Agent Activity






SITC 2023 Data Further Supports PORT-2 Favorable Safety & Tolerability Profile At All Doses Tested to Date



Table 1: Demographics and Baseline Characteristics (n=12)			
Tumor type (%)	Melanoma: 6 (43) NSCLC 8 (57)		
Age (range)	63 (41,79)		
Median prior therapies (range)*	4 (2,7)		
Prior PD-1* (%)	12 (100)		
Performance status (%)	ECOG 0: 9 (64) ECOG 1: 5 (36)		

Exposure

- A total of 65 infusions given to 14 patients at doses up to 9 mg/m², with a median of 5 doses per patient
- Pk shows long plateau and limited volume of distribution



Adverse Event	Grade 1	Grade 2	Grade 3-5
Bullous pemphigoid	1 (7%)	0	0
Cough	1 (7%)	0	0
Diarrhea	1 (7%)	0	0
Dizziness	2 (14%)	0	0
Dry mouth	1 (7%)	0	0
Dyspnea	1 (7%)	0	0
Fatigue	1 (7%)	1 (7%)	0
Flu-like symptoms	1 (7%)	0	0
Hair Loss	1 (7%)	0	0
Headache	1 (7%)	0	0
Hypertension	0	1 (7%)	0
Hyponatremi a	1 (7%)	0	0
Fever	1 (7%)	0	0
Nausea	1 (7%)	0	0
Pruritus	1 (7%)	0	0
AST/ALT elevation	2 (14%)	0	0
Vomiting	1 (7%)	0	0


Safety

- No DLT's, related SAEs, or G3-5 related AEs
- Only G1 related AEs have been observed at the highest dose of PORT-2
- Patient treated with PORT-2 + pembrolizumab(n=2) experienced only lowgrade AEs consistent with the safety profile of pembrolizumab




SITC 2023 - Early Evidence of Single Agent Activity for PORT-2 in Advanced Melanoma & NSCLC





- Serum biomarker analyses provide evidence of iNKT, NK, DC activation, as well as increases in antigen-presenting CD86+ B cells following treatment with PORT-2
- Combination with an anti-PD1 antibody is ongoing, with encouraging preliminary reduction in liver lesions observed

 Example patient treated at 3mg/m² had mixed response (melanoma patient failed anti-PD-1 and targeted therapy)




Mediastinal Lesion Decreased from 4cm to 1.9cm

- Based on the favorable safety and tolerability data at all doses tested to date, the Phase 1 portion of this trial is expanding to evaluate higher dose levels; Data anticipated by Q1 2024
- Phase 2 to commence upon completion of Phase 1 dose escalation



IMPORT-201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma*





Adenosine Portfolio


Validated mechanism impacting multiple immune cells

Opportunity to modulate adenosine in 4 different ways:

PORT-6 A2AR Antagonist PORT-7 A2BR Antagonist PORT-8 A2AR/A2BR Dual Antagonist PORT-9 Gut-Restricted A2BR Antagonist








16 Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function; Virgano, et al; Frontiers in Immunology 2019 modified slightly and used under CC BY 4.0



Difference in A2A Small Molecules

17

Portage's PORT-6 is best in class for potency, selectivity and durability*




<u>Fast Follower</u> with Precedent for Biomarker Selection Enrich patient population with biomarker/clinical data





-			
Tumor type	% A2A high*		
RCC	50		
BC	38		
NSCLC	34		
Gastric	32		
Prostate	26		





High potency and selectivity may provide important safety and efficacy advantages

Activity in 4T1, CT26, and other disease models (asthma, fibrosis, sickle cell)

Functional Receptor Antagonism		Bir	nding Affinity	,	
Receptor	Ki (nm)	Selectivity	Receptor	Ki (nm)	Selectivity
A2B	9	1	A2B	13	1
A1	>30,000	>3000x	A1	300	23x
A2A	>10,000	>1000x	A2A	1,800	138x
A3	>30,000	>3000x	A3	60,000	>4,000x

Portage only company believed to be developing potent/selective A2B inhibitor

19 Data on File


portage

ADPORT-601: Adaptive Phase 1a/1b Study *



A2AR (PORT-6) indications: Prostate Cancer, Non-small Cell Lung Cancer, Head & Neck Cancer, Renal Cell Cancer with high A2A expression

A2BR (PORT-7) indications: Colorectal Cancer, Non-small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer, Prostate Cancer with high A2B expression




portage

Broad and deep intellectual property covering:

iNKT Adenosine Nanolipogel & **VLP** Delivery **DNA** Aptamers Platform Antagonist Engager · Composition, Composition of matter · Optimized co-delivery · First-in-class systemic STING agonist formulations with patents platforms antigens, other I/O Use patents filed New IP for aptamers agents · Composition patents for · Liposomes/particles products 2031-2041 >60 Many Applications Pending Worldwide **Issued Patents** Patent Exclusivity



Key Upcoming Clinical Development Milestones*





portage

Summary Financial Data

Cash Balance (6/30/23)	~\$7.7 million+
Committed Purchase Lincoln Park Capital Available*	\$28.0 million
Debt	\$-
Shares Outstanding (08/29/23)	17,801,391*
Insider Ownership	42.61%
Public Float	57.39%
Options & RSUs Outstanding (6/30/23)	2,342,160
Cash Burn During Quarter Ended 6/30/23	\$(~2.8 million)

+ Pro forma Cash Balance is approximately \$13 million, as adjusted, giving effect to \$6 million financing, net of expenses, closed on October 3, 2023 ("the Financing") * Pro forma shares of 20,944,185, as adjusted, giving effect to Financing for 3,157,895 or common stock equivalents and issuance of Series A, B, C Warrants to purchase up to 9,473,685 ordinary shares

*Portage has right (sole discretion/no obligation), to sell up to \$30 million shares over agreement's 36-month term based on prevailing market prices at the time of each sale, subject to certain conditions. As of 8/29/23, approximately \$28.0 million are available proceeds under the Purchase Agreement, subject to Baby Shelf Rule limitations and contractual lock-up restrictions from Financing.

Accelerating I/O Development in Untapped Growth Areas



* depending data and available liquidity

portage